Indoco Remedies has successfully secured EU GMP certification for its manufacturing facility located in Goa. According to reports from CNBC TV18, the certification was granted by the Malta Medicines Authority following a comprehensive inspection process. The facility specializes in manufacturing solid oral dosage forms and has now been officially recognized as meeting international quality standards. As per the latest company announcement, this certification represents a significant milestone that reinforces the company's commitment to maintaining high-quality standards in pharmaceutical manufacturing.
The certification process involved a thorough inspection conducted by the Malta Medicines Authority from November 19 to November 24, 2025. As reported by CNBC TV18, this inspection covered the company's manufacturing facility for solid oral dosage forms, specifically referred to as Plant I. The facility's compliance with Good Manufacturing Practice requirements was assessed during this inspection period, with the inspection results confirming compliance with Good Manufacturing Practice requirements as per the EC Directive. The regulator confirmed that the plant complies with the Good Manufacturing Practice requirements prescribed under the relevant European Commission directive.
The Goa certification adds to a growing list of regulatory approvals secured by Indoco Remedies in recent months. In May 2025, the company's oral solid dosage manufacturing facility at Baddi, Himachal Pradesh, received EU GMP certification from the German Health Authority in Berlin following an inspection conducted in April. The latest development involves the Baddi facility (Plant III) receiving EU GMP certification from the German Health Authority in May 2026, with the inspection conducted from April 22 to 27, 2026. This inspection confirmed that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive, further strengthening the company's export capabilities across multiple production sites.
The regulatory milestone comes as Indoco Remedies works towards improving its financial performance. For the quarter ended March 2026, the company reported a net loss of ₹22 crore, compared with a loss of ₹40 crore a year earlier. Revenue rose 22% year-on-year to ₹476 crore from ₹390 crore. Operational performance showed significant improvement with EBITDA at ₹50.2 crore against an EBITDA loss of ₹1 crore in the corresponding quarter last year, while EBITDA margin improved to 10.6%. For FY26, Indoco reported revenue of ₹1,633.5 crore, up from ₹1,494.8 crore in the previous financial year, with annual EBITDA increasing to ₹157.2 crore from ₹128 crore, reflecting better operating leverage and gradual recovery in business performance.
Shares of Indoco Remedies are likely to remain in focus following the certification announcement, as reported by Moneycontrol. Commenting on the development, Ms. Aditi Panandikar, Managing Director of Indoco Remedies, emphasized the strategic importance of this certification, stating that "Compliance is a core value that drives our quality systems. This approval reinforces our commitment to delivering the highest quality healthcare to our customers worldwide." The EU GMP certification enables the company to serve European markets with products manufactured under EU-compliant standards, strengthening its global pharmaceutical manufacturing capabilities and supporting its export-focused strategy across multiple manufacturing facilities.
